Immunotherapy Extends Disease-Free Lung Cancer Survival
Patients with resected lung cancer saw longer disease-free survival with pembrolizumab, though overall survival remained unchanged.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Should medical studies prioritize overall survival rates over disease-free survival in determining drug efficacy?
The immunotherapy drug pembrolizumab improved disease-free survival in patients with resected stage IB to IIIA non-small cell lung cancer, though final trial data shows no benefit to overall survival. This study offers key insights for patients currently discussing adjuvant treatment options with their oncology care teams.
Why it matters
While the treatment helps extend the time patients remain free of disease, the lack of an overall survival benefit highlights the trade-off between cancer recurrence reduction and potential side effects. These findings provide clarity on the long-term effectiveness of adding immunotherapy after surgical lung cancer resection.
In the phase 3 PEARLS/KEYNOTE-091 trial of 1,177 patients, those receiving pembrolizumab saw a median disease-free survival of 58.7 months compared to 43.3 months for the placebo group. Six-year data showed overall survival rates of 68.5% for the treatment arm and 66.4% for placebo, a difference that did not reach statistical significance.
The players
ESMO Congress
An international platform for oncology professionals to share findings from major clinical trials in cancer research.
The details
Patients in the treatment group received 200 mg of pembrolizumab intravenously every three weeks for up to 18 doses following complete surgical resection. The immunotherapy works by blocking the PD-1 protein on immune cells, which helps the body identify and attack cancer cells that may remain after surgery. However, the study also found that 34.0% of patients receiving pembrolizumab experienced grade 3 to 5 adverse events, compared to 25.6% in the placebo group, with 17.1% of treated patients discontinuing therapy due to toxicity.
Timeline
January 26, 2023: FDA approval of pembrolizumab for NSCLC adjuvant treatment.
January 21, 2026: Data cutoff for the trial final analysis.
October 23-27, 2026: Presentation of trial findings at ESMO Congress in Madrid, Spain.
Health Landscape
The PEARLS/KEYNOTE-091 trial represents a major effort to define the role of adjuvant immunotherapy in early-stage lung cancer care. These results refine the historical expectation that reducing disease recurrence after surgery would inherently lead to longer overall survival.
Patients considering adjuvant therapy should discuss the balance of potential disease-free survival gains against the risks of immune-related side effects. Reviewing your specific stage of lung cancer with your oncologist can help determine if this treatment pathway is appropriate for your care plan.
The takeaway
While pembrolizumab may extend disease-free intervals, it does not guarantee longer overall survival in this population. Patients should weigh these findings with their care team and prioritize monitoring for serious adverse events if immunotherapy is initiated.
Further reading
For more on evolving research in this area, see our Cancer section.
More information
Review the full details of the KEYNOTE-091 clinical trial registry on the official government portal.
Source note: This article includes information reported by OncLive.
Live Poll
Should medical studies prioritize overall survival rates over disease-free survival in determining drug efficacy?
